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Abstract
Background: Little is known about the influence of antiretroviral therapy with or without micronutrient supplementation
on the micronutrient concentrations of HIV-infected lactating women in resource-constrained settings.
Objective: We examined associations of highly active antiretroviral therapy (HAART) and lipid-based nutrient supplements (LNS)
with concentrations of selected micronutrients in HIV-infected Malawian women at 24 wk postpartum.
Methods: Plasmamicronutrient concentrations weremeasured in a subsample (n = 690) of Breastfeeding, Antiretrovirals,
and Nutrition (BAN) study participants who were randomly assigned at delivery to receive HAART, LNS, HAART+LNS, or
no HAART/no LNS (control). HAART consisted of protease inhibitor–based triple therapy. LNS (140 g/d) met energy and
micronutrient requirements of lactation. Multivariable linear regression tested the association of HAART and LNS, plus
their interaction, with micronutrient concentrations, controlling for season, baseline viral load, and baseline CD4 count.
Results: We found significant HAART by LNS interactions for folate (P = 0.051), vitamin B-12 (P < 0.001), and transferrin
receptors (TfRs) (P = 0.085). HAART was associated with lower folate (with LNS:227%, P < 0.001; without LNS:212%,
P = 0.040) and higher TfR concentrations (with LNS: +14%, P = 0.004; without LNS: +28%, P < 0.001), indicating iron
deficiency. LNS increased folate (with HAART: +17%, P = 0.037; without HAART: +39%, P < 0.001) and decreased TfR
concentrations (with HAART only:212%, P = 0.023). HAART was associated with lower vitamin B-12 concentrations only
when LNS was present (218%, P = 0.001), whereas LNS increased vitamin B-12 only when no HAART was present
(+27%, P < 0.001). HAART, but not LNS, was associated with higher retinol-binding protein (RBP; +10%, P = 0.007). We
detected no association of HAART or LNS with selenium, ferritin, or hemoglobin.
Conclusion: The association of HAART with lower folate, iron deficiency, and higher RBP plus the attenuation of LNS
effects on folate and vitamin B-12 when combined with HAART has implications for the health of lactating HIV-infected
women taking HAART in prevention of mother-to-child transmission programs. This trial was registered at clinicaltrials.gov
as NCT00164736. J Nutr 2015;145:1950–7.
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Introduction
The WHOs latest update on the use of antiretrovirals for the
prevention of mother-to-child transmission (PMTCT)12 has
precipitated a shift toward the provision of antiretrovirals to
mothers rather than to infants in African countries with high
HIV prevalence (1, 2). More than 1.5 million women are now
1 The Breastfeeding, Antiretrovirals, and Nutrition (BAN) study was supported by
grants from the Prevention Research Centers Special Interest Project of the
CDC (SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP000059-01, and SIP
22-09 U48-DP001944-01), the Bill & Melinda Gates Foundation (OPP53107), the
National Institute of Allergy and Infectious Diseases, the University of North
Carolina Center for AIDS Research (P30-AI50410), the Carolina Population Center
(R24 HD050924), the NIH Fogarty AIDS International Training and Research
Program (DHHS/NIH/FIC 2-D43 TW001039), and Fogarty International Clinical
Research Scholars (R24TW007988; the American Recovery and Reinvestment
Act). The antiretrovirals used in the BAN study were donated by Abbott
Laboratories, GlaxoSmithKline, Boehringer Ingelheim, Roche Pharmaceuticals,
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eligible to receive highly active antiretroviral therapy (HAART),
containing a combination of 3 drugs, either during pregnancy
and breastfeeding (Option B) or starting in pregnancy and
continuing for life (Option B+) (3). Although these strategies
have clear benefits for preventing vertical transmission, the long-
term effects of HAART on the micronutrient status of women
participating in PMTCT programs are not well characterized.
Marginal micronutrient status and deficiencies are common
among HIV-infected women in resource-limited countries (4–7).
In patients with low CD4 counts, HAART has a beneficial
impact onmicronutrient status through reductions in anemia (8–
10) and vitamin A (11) and selenium deficiency (12). It is not
known if these positive effects of HAART on the status of some
micronutrients occur in individuals with higher CD4 and/or
minimal HIV disease progression, like many mothers in PMTCT
programs. Some negative effects of antiretrovirals on micro-
nutrient concentrations have been reported, particularly for
vitamins D (13, 14) and B-12 (15, 16). Negative associations of
antiretrovirals used for PMTCT with maternal micronutrient
concentrations have implications for the health of the mother
and her child, through micronutrient stores obtained in utero
and micronutrients available in breast milk. In the pre-HAART
era, micronutrient supplementation provided to people living
with HIV improved their hematologic status (17–25). However,
the association of micronutrient supplementation with plasma
micronutrient concentrations in lactating women receiving
HAART is unknown.
This article presents data from a selected subsample of
women who participated in the Breastfeeding, Antiretrovirals,
and Nutrition (BAN) study in Malawi. We examine the
association of micronutrient-fortified lipid-based nutrient sup-
plements (LNS) and protease inhibitor–based HAART regimens
on maternal micronutrient concentrations. We focus on associ-
ations at 24 wk, the time at which participants had their longest
exposure to study interventions.
Methods
Subjects and procedures. From 2004 to 2009, HIV-1–infected,
pregnant women were recruited into the BAN study at antenatal clinics
in Lilongwe, Malawi. They received the standard of care during
pregnancy from local health facilities. Mother-infant pairs were eligible
for enrollment at delivery if infants had a birth weight $2 kg and
mothers had a CD4 count $250 cells/mm3 ($200 cells/mm3 until July
2006), hemoglobin $ 70 g/L, and no previous antiretroviral use (26).
At delivery, womenwere randomly assigned to the following maternal
interventions: HAART, LNS, HAART+LNS, and no HAART/no LNS
(control). Micronutrient biomarkers were analyzed in a subsample of
stored plasma from BAN participants. We used all 24-wk specimens with
a matched infant sample and available anthropometric and dietary data.
Mothers were excluded if they had multiple births or their infants became
HIV-positive, because we also planned to use the subsample to analyze the
relation between maternal supplementation and infant growth. Multiples
and HIV-positive infants have different rates of growth than do singletons
and HIV-negative infants.
Nutrition and antiretroviral interventions were provided from
delivery through 28 wk postpartum. Mothers were counseled to
exclusively breastfeed from 0 to 24 wk and to wean their infants
between 24 and 28 wk. LNS (Nutriset), containing peanut paste, nonfat
milk powder, sugar, vegetable oil, and micronutrient mix, was used for
the nutrition intervention. The daily LNS dose (140 g) was designed to
supply the additional energy, protein, and micronutrient needs of
lactation. It provided 3120 kJ (746 kcal) of energy, 20.8 g protein, and
16 vitamins and minerals. The complete nutrient content of the LNS is
described elsewhere (27). Briefly, it contained 300mg folic acid (0.6 times
the RDA for lactating women), 2.6 mg cyanocobalamin (0.9 times the
RDA), 75 mg sodium selenite (1.3 times the RDA), and 15 mg ferrous
sulfate (1.7 times the RDA) (28–30). The LNS did not contain vitamin A
due to evidence available before the start of the study that it could
increase HIV transmission through breast milk (31).
The maternal antiretroviral intervention was a HAART regimen
containing 3 drugs (32). All women assigned to the antiretroviral arms
received lamivudine/zidovudine as a single pill (Combivir; Glaxo-
SmithKline) throughout the intervention period (0–28 wk). In addition,
the first 39 BAN participants randomly assigned to antiretrovirals
received nevirapine as their study drug. The study switched to the
second-line drug, nelfinavir (Viracept; Roche), which was given to the
next 146 women, after the FDA issued a black box warning concerning
the use of nevirapine in women with a CD4 count >250 cells/mm3. A
further change was made to lopinavir/ritonavir (LPVr; Kaletra; Abbott)
for reasons of availability, safety, and potency. Nelfinavir and LPVr are
protease inhibitors, which have side effects including nausea, diarrhea,
increased lipids, and lipodystrophy (33). In our micronutrient subsam-
ple, 3 women switched from nevirapine to nelfinavir, one switched from
nelfinavir to LPVr, and one switched from LPVr to nelfinavir (due to
reactions to LPVr). We coded these women as taking the drug used at the
24-wk visit.
Venous blood samples were collected at 24 wk postpartum. Plasma
was separated from RBCs within 60 min, separated into aliquots in
polypropylene storage tubes, and kept at270C. Mothers were asked to
report their adherence to the LNS at 1, 4, 8, 12, and 21 wk. Adherence to
HAART was based on pill counts at 4, 12, and 18 wk. This was
calculated by using the following formula: (number of pills distributed at
previous visit – number of pills returned at current visit)/(days between
visits 3 pills prescribed per day). Adherence to the LNS regimen was
obtained by questionnaire during regular study visits. Mothers were
asked how much of the supplement they ate yesterday in half-packet
increments, ranging from none to 2 packets (the full daily dose). A
questionnaire on socioeconomic characteristics was administered to
mothers during screening.
At the time when this study began, there was not yet evidence that
antiretrovirals were effective at preventing HIV transmission through
breast milk and it was acceptable to have study groups without drugs. In
2008, the studys data safety and monitoring board stopped enrollment
in the control arm when it became clear that use of antiretrovirals
prevented transmission. Ethical approval for the study was obtained
from the Malawi National Health Science Research Committee and the
institutional review boards at the University of North Carolina at Chapel
Hill, the US CDC, and the University of California, Davis. The trial was
registered at clinicaltrials.gov (NCT00164736).
Laboratory analysis. Plasma concentrations of most micronutrient
biomarkers were measured at the USDA–Agricultural Research Service
Western Human Nutrition Research Center. Vitamin B-12 and folate
were analyzed by using the SimulTRAC-SNB Radioassay Kit [vitamin B-
12 (57Co)/folate (12585 I); MP Biomedicals]. The analysis of retinol-
binding protein (RBP) was performed with the Human Retinol BP
ELISA, an immunoperoxidase assay for the determination of RBP in
and Bristol-Myers Squibb. The Call to Action Prevention of Mother-to-Child
Transmission Program, from which BAN mothers were recruited, was supported
by the Elizabeth Glaser Pediatric AIDS Foundation, the United Nations Childrens
Fund, the World Food Program, the Malawi Ministry of Health and Population,
Johnson & Johnson, and the US Agency for International Development.
2 Author disclosures: VL Flax, LS Adair, LH Allen, S Shahab-Ferdows, D Hampel,
CS Chasela, G Tegha, EJ Daza, A Corbett, NL Davis, D Kamwendo, AP Kourtis, DJ
Jamieson, and ME Bentley, no conflicts of interest. CM van der Horst received
grant support from Abbott Laboratories and GlaxoSmithKline.
3 Supplemental Table 1 is available from the ‘‘Online Supporting Material’’ link in
the online posting of the article and from the same link in the online table of
contents at http://jn.nutrition.org.
12 Abbreviations used: AGP, a-1-acid glycoprotein; BAN, Breastfeeding,
Antiretrovirals, and Nutrition; CRP, C-reactive protein; HAART, highly active
antiretroviral therapy; LNS, lipid-based nutrient supplements; LPVr, lopinavir/
ritonavir; MRP, multidrug resistance–related protein; PMTCT, prevention of
mother-to-child transmission; RBP, retinol-binding protein; TfR, transferrin receptor.
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human sera (Immunology Consultants Laboratory). Transferrin recep-
tors (TfRs) and inflammatory markers [C-reactive protein (CRP) and a-1-
acid glycoprotein (AGP)] were measured by using a Cobas Integra 400+
analyzer (Roche Diagnostics). Ferritin concentrations were determined
with the IRMA Ferritin Coat-a-Count radioimmunoassay (Siemens
Health Care Diagnostics).
Selenium concentrations were analyzed at the USDA–Agricultural
Research Service Grand Forks Human Nutrition Research Center by
automated electrothermal atomic absorption spectrophotometry. He-
moglobin was measured in whole blood in Lilongwe by using a Beckman
Coulter AcT 5-part Differential Analyzer (Beckman Coulter).
Statistical analysis. Differences in background characteristics of
participants and adherence to LNS and HAART by study group were
examined by using ANOVA for continuous variables and chi-square tests
for categorical variables. Natural-log transformations were used for all
micronutrient outcome variables because they followed non-Gaussian
distributions; outcomes were modeled as continuous variables. Multi-
variable linear regression was used to test associations between the LNS
and HAART interventions and maternal plasma micronutrient concen-
trations. Adjusted geometric means for each intervention group and
ratios for pairs of interventions (e.g., HAART vs. no HAART) and their
95%CIs were calculated from the models. A HAART3 LNS interaction
term was included in all initial models and retained if P < 0.10. For
micronutrients with significant HAART 3 LNS interactions, explor-
atory analyses were conducted to examine possible differential effects of
regimens containing LPVr + Combivir or nelfinavir + Combivir. In
exploratory models, we estimated ratios of geometric means for pairs of
groups (e.g., LPVr vs. no HAART among women receiving LNS). All
models controlled for baseline CD4 count and log10 viral load as








(n = 111) P
Age, y 26.6 6 5.0 26.6 6 5.1 27.3 6 4.9 26.0 6 5.2 0.36
More than primary education, % 34 39 37 35 0.64
Number of pregnancies 3.4 6 1.7 3.3 6 1.6 3.4 6 1.4 3.4 6 1.8 0.96
BMI
At 24 wk, kg/m2 22.7 6 2.8 22.8 6 3.4 22.3 6 3.3 22.3 6 2.6 0.29
,18.5 kg/m2 at 24 wk, % 4 4 7 6 0.62
Viral load at baseline,2 log10 copies 4.1 6 0.9 4.1 6 0.9 4.2 6 0.9 4.2 6 0.9 0.93
CD4
At baseline,2 cells/μL 428 (327, 577) 444 (323, 600) 460 (304, 571) 449 (336, 580) 0.90
At 24 wk,3 cells/μL 474 (326, 655) 462 (337, 698) 634 (470, 774) 628 (434, 796) ,0.001
,250 cells/mm3 at 24 wk, % 9 10 2 4 0.03
Hemoglobin at baseline,2 g/L 109 6 1.2 107 6 1.2 107 6 1.2 108 6 1.1 0.33
Anemia
Hemoglobin ,120 g/L at baseline,2 % 54 58 55 52 0.76
Hemoglobin ,120 g/L at 24 wk, % 36 32 38 35 0.75
CRP .5 mg/L at 24 wk, % 19 16 18 14 0.69
AGP .1 g/L at 24 wk, % 36 35 34 31 0.82
1 Values are means 6 SDs or medians (IQRs) unless otherwise indicated; n = 690. AGP, a-1-acid glycoprotein; BAN, Breastfeeding,
Antiretrovirals, and Nutrition; CRP, C-reactive protein; HAART, highly active antiretroviral therapy; LNS, lipid-based nutrient supplements.
2 Baseline viral load, CD4, hemoglobin, and anemia were measured during pregnancy when participants were screened.
3 CD4 at 24 wk: no LNS/no HAART, n = 211; LNS, n = 213; HAART, n = 92; LNS + HAART, n = 105.
TABLE 2 Folate, vitamin B-12, and TfR concentrations at 24 wk postpartum in a sample of BAN study
mothers who were untreated or given HAART with or without LNS1
HAART No HAART Ratio of HAART to no HAART (95% CI)
Folate, nmol/L
LNS 19.1 (17.1, 21.1) 26.0 (24.2, 27.8) 0.73*** (0.65, 0.83)
No LNS 16.3 (14.6, 18.0) 18.7 (17.4, 20.0) 0.88* (0.77, 0.99)
Ratio of LNS to no LNS 1.17* (1.01, 1.35) 1.39*** (1.26, 1.54)
Vitamin B-12, pmol/L
LNS 286 (257.4, 313.7) 349 (325.7, 372.2) 0.82** (0.73, 0.92)
No LNS 310 (278.4, 341.1) 276 (257.4, 294.1) 1.12 (0.99, 1.27)
Ratio of LNS to no LNS 0.92 (0.80, 1.06) 1.27*** (1.15, 1.39)
TfR, mg/L
LNS 5.0 (4.6, 5.3) 4.3 (4.1, 4.6) 1.14** (1.04, 1.25)
No LNS 5.6 (5.2, 6.0) 4.4 (4.2, 4.6) 1.28*** (1.17, 1.40)
Ratio of LNS to no LNS 0.88* (0.79, 0.98) 0.98 (0.92, 1.06)
1 Values are adjusted geometric means (95% CIs) or ratios (95% CIs). Folate and vitamin B-12: no HAART, no LNS, n = 237; no HAART,
LNS, n = 238; HAART, no LNS, n = 103; HAART, LNS, n = 110. TfR: no HAART, no LNS, n = 237; no HAART, LNS, n = 238; HAART, no
LNS, n = 104; HAART, LNS, n = 111. Models controlled for season, baseline CD4 count, baseline viral load, and use of folate inhibitors (for
folate only) and included significant HAART 3 LNS interactions (folate: P = 0.051; vitamin B-12: P , 0.001; TfR: P = 0.085).
*,**,***Significant ratio: *P , 0.05, **P , 0.01, ***P , 0.001. BAN, Breastfeeding, Antiretrovirals, and Nutrition; HAART, highly active
antiretroviral therapy; LNS, lipid-based nutrient supplements; TfR, transferrin receptor.
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continuous variables. Season at the time of the 24-wk visit was also
included in the models to control for potential differences in dietary
intake and to account for the possibility that calendar time was related to
the outcomes. Season was included as a binary variable denoting the
presence or absence of the food-insecure period of the year (during the
rainy season) based on the month and date of the womans study visit.
Approximately 10% of the analysis sample received either sulfadoxine-
pyrimethimine or cotrimoxazole (drugs with folate-inhibiting proper-
ties) during the 3 wk preceding the study visit when blood was collected.
Consequently, the presence or absence of folate-inhibiting drugs was
included in the folate model. To better understand the role of
inflammation on the association of antiretrovirals with micronutrients,
we compared multivariable linear regression models with and without
markers of inflammation (measured as log CRP and log AGP and
modeled as continuous variables) for biomarkers that are known to be
influenced by the acute phase response (selenium, RBP, ferritin, TfR, and
hemoglobin) (34).
Results
Of 709 women selected for the micronutrient subsample at 24
wk, 18 were dropped from the analysis. Nine of these stopped
taking their drugs before 24 wk and 9 were taking nevirapine, a
sample that was too small to produce stable estimates in
regression models. There were no significant differences by study
group in age, level of education, number of pregnancies, BMI,
baseline viral load or CD4 count, anemia, high CRP, or high
AGP (Table 1). As expected, we found significantly lower
median CD4 counts and percentage of CD4 <250 cells/mm3
among women in the groups that received no HAART at 24 wk
compared with those who received HAART. Characteristics of
mothers in the micronutrient subsample compared with those of
other BAN participants are shown in Supplemental Table 1.
Adherence to LNS and HAART was high and generally
increased over time. The percentages of mothers who reported
consuming the full dose (2 packets) of LNS the previous day
were as follows: 1 wk, 87%; 4 wk, 89%; 8 wk, 94%; 12 wk,
94%; and 21 wk, 96%. On the basis of pill counts, mean drug
adherence was 86% at 4 wk, 87% at 12 wk, and 90% at 18 wk.
LNS adherence did not differ significantly between the LNS and
HAART+LNS groups at any visit. Similarly, there were no
differences in drug adherence by type of HAARTor between the
groups receiving HAARTwith or without LNS.
We found significant interactions of HAART and LNS for
folate (P = 0.051), vitamin B-12 (P < 0.001), and TfR (P = 0.085)
but not for selenium, RBP, ferritin, or hemoglobin. Folate
concentrations were higher among women receiving LNS with
HAART (+17%; P = 0.037) or without HAART (+39%; P <
0.001) (Table 2). HAART was associated with lower folate
concentrations in women receiving LNS (227%; P < 0.001) or
no LNS (212%; P = 0.040). Vitamin B-12 concentrations were
higher among women who received LNS and noHAART than in
those receiving no LNS and no HAART (+27%; P < 0.001).
HAARTwas associated with lower vitamin B-12 concentrations
in women who received LNS (218%; P = 0.001) but not in those
with no LNS. Compared with women not receiving HAART,
TfR concentrations were higher in women receiving HAART
with (+14%; P = 0.004) or without (+28%; P < 0.001) LNS.
Among women receiving HAART, TfR concentrations were
lower in women receiving LNS (212%; P = 0.023).
In exploratory analyses by type of drug regimen, the ratio of
the geometricmeans indicated that women taking LPVr had lower
folate concentrations if they received LNS (235%; P < 0.001) or
no LNS (217%; P = 0.031), whereas women taking nelfinavir
had lower folate only if they received LNS (225%; P = 0.006)
(Figure 1A). Women taking LPVr had lower vitamin B-12
concentrations if they received LNS (224%; P = 0.001) but not
if they did not receive LNS (Figure 1B). In contrast, women
taking nelfinavir had higher vitamin B-12 concentrations if
they received no LNS (+20%; P < 0.022) but not in those who
received LNS. LNS increased folate and vitamin B-12 concen-
trations in women receiving no drugs (folate: +33%, P < 0.001;
vitamin B-12: +24%, P < 0.001) but not in women receiving
either LPVr or nelfinavir. Women taking LPVr had higher TfR
FIGURE 1 Adjusted geometric mean plasma folate (A), vitamin
B-12 (B), and TfR (C) concentrations at 24 wk postpartum in a sample
of BAN study mothers who were untreated or given HAART with or
without LNS. Values are geometric means and 95% CIs. (A and B) No
HAART, no LNS: n = 237; no HAART, LNS: n = 238; NLF, no LNS:
n = 43; NLF, LNS: n = 43; LPVr, no LNS: n = 60; LPVr, LNS: n = 67. (C)
No HAART, no LNS: n = 237; no HAART, LNS: n = 238; NLF, no LNS:
n = 44; NLF, LNS: n = 44; LPVr, no LNS: n = 60; LPVr, LNS: n = 67.
Comparisons were made between no LNS and LNS within each drug
category (no HAART, NLF, and LPVr) and between NLF or LPVr and no
HAART within each LNS category. *,**,***Difference between
adjusted means at either end of the bar: *P , 0.05, **P , 0.01,
***P , 0.001. BAN, Breastfeeding, Antiretrovirals, and Nutrition;
HAART, highly active antiretroviral therapy; LNS, lipid-based nutrient
supplements; LPVr, lopinavir/ritonavir; NLF, nelfinavir; TfR, transferrin
receptor.
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only if they received no LNS (+20%; P < 0.001) (Figure 1C).
Women taking nelfinavir had higher TfR if they received LNS
(+25%; P < 0.001) or no LNS (+31%; P < 0.001). LNS was
associated with lower TfR only in women receiving LPVr
(215%; P = 0.031); a similar association was not detected
among women receiving nelfinavir.
We found no significant interactions of HAARTand LNS for
RBP, selenium, ferritin, or hemoglobin (Table 3). RBP concen-
trations were higher among women taking HAART than among
those with no HAART (RBP: +10%; P = 0.007), but no
associations with LNS were detected. There were no associa-
tions of either intervention with concentrations of selenium,
ferritin, or hemoglobin.
CRP, an acute phase protein, was negatively associated with
RBP (P < 0.001) and hemoglobin (P < 0.001) and positively
associated with ferritin (P < 0.001). AGP, a marker of chronic
infection, was negatively associated with selenium (P < 0.001)
and hemoglobin (P < 0.001). Including CRP and AGP in the
models did not appreciably change the coefficients for selenium,
RBP, ferritin, TfR, or hemoglobin (data not shown).
Discussion
This study examined the association of protease inhibitor–based
HAART and LNS with maternal micronutrient concentrations
after 24 wk of use. Women in this subsample had high mean
CD4 counts and were assigned to HAART to test whether it
prevented HIV transmission to their infants. Micronutrient
concentrations and supplementation interventions have not been
studied previously in women taking HAART for PMTCT. Yet,
such women represent an important and growing population of
HAART users due to the recent changes in recommendations to
provide lifelong antiretrovirals to mothers in Option B+ PMTCT
programs and to initiate HAART for all HIV-infected individ-
uals with a CD4 count <500 cells/mm3 (1, 2).
We found that maternal folate concentrations were higher in
women receiving LNS and lower in women receiving HAART.
Furthermore, HAART modified the effect of LNS on folate.
Intermediate folate values for the combined interventions
suggest that HAART diminished the benefits of supplementa-
tion, whereas a daily dose of 0.6 times the RDA of folic acid
mitigated the negative influence of the drugs. Our finding that
protease inhibitor–based therapy was associated with lower
folate concentrations confirms results from small cross-sectional
studies in children and adults (35, 36). Lower folate concentra-
tions among participants receiving HAART could be related to
poor absorption due to drug-related changes in gut epithelial
integrity (37) or drug-related diarrhea, which commonly occurs
with initiation of protease inhibitors and some other antire-
troviral drugs (38, 39). It is possible that HAART is related to
intracellular folate metabolism. Some classes of antiretrovirals
inhibit multidrug resistance–related proteins (MRPs), including
MRP3, which is involved in folic acid transport out of the gut
(40). Folate and homocysteine have an inverse relation in HIV-
infected individuals. Several studies found an association of
antiretroviral therapy or duration of therapy with hyper-
homocysteinemia and low folate concentrations (35, 36, 41,
42), whereas others detected no association (43–45). Additional
research is needed to confirm the relation between folate and
different types and combinations of antiretrovirals and to clarify
the biological mechanisms.
In our sample, LNS supplementation was associated with
higher vitamin B-12 concentrations only in women not taking
HAART and HAART was associated with lower vitamin B-12
concentrations only in women receiving LNS, indicating that
HAART eliminated the association of LNS with vitamin B-12.
This was driven by the negative association of LPVr with vitamin
B-12 in women receiving LNS. Other studies also showed that
vitamin B-12 concentrations can be increased through vitamin
B-12 supplementation in HIV-infected children and adults,
especially if they are initially deficient (16, 46, 47). Evidence
from previous research on the effects of antiretrovirals on vitamin
B-12 concentrations or status is mixed. One study found that
zidovudine treatment was associated with lower plasma vitamin
B-12 concentrations (15). A second study showed that vitamin
B-12 intake was related to larger increases in serum vitamin B-12
concentrations in individuals not taking protease inhibitors than
in those taking protease inhibitors (16). However, a third study
found that patients receiving HAART (type not described) had
higher vitamin B-12 concentrations and were less likely to be
vitamin B-12 deficient than a historical cohort of patients who
were not taking HAART (48). The mixed evidence for the effects
of antiretrovirals on vitamin B-12 concentrations indicates a need
for further research in larger samples and with adequate infor-
mation on the type of drugs and adherence.
The literature on the association of HAART and vitamin A
concentrations is also mixed. Participants in this study had
higher RBP concentrations when they received HAART, even
when controlling for concurrent markers of inflammation and
baseline CD4 and viral load. Because RBP has a 1:1 relation with
serum retinol (49), this finding suggests that protease inhibitor–
based HAART could contribute to improved vitamin A status in
populations similar to that in the BAN study, with high baseline
TABLE 3 Selenium, RBP, ferritin, and hemoglobin concentrations at 24 wk postpartum in a sample of
BAN study mothers who were untreated or given HAART with or without LNS1
HAART No HAART
Ratio of HAART
to no HAART LNS No LNS
Ratio of LNS
to no LNS
Selenium, μg/L 82.0 (79.5, 84.6) 81.7 (80.0, 83.4) 1.00 (0.97, 1.04) 82.9 (80.8, 84.9) 80.7 (78.8, 82.7) 1.03 (0.99, 1.06)
RBP, μmol/L 0.98 (0.92, 1.03) 0.89 (0.86, 0.93) 1.10** (1.03, 1.17) 0.92 (0.88, 0.96) 0.92 (0.88, 0.96) 1.00 (0.94, 1.07)
Ferritin, μg/L 22.4 (19.8, 24.9) 24.5 (22.6, 26.4) 0.91 (0.79, 1.05) 24.7 (22.5, 27.0) 23.0 (20.9, 25.0) 1.08 (0.95, 1.22)
Hemoglobin, g/L 123 (121.8, 125.1) 123 (121.5, 123.7) 1.00 (0.99, 1.02) 123 (121.8, 124.4) 123 (121.2, 123.9) 1.00 (0.99, 1.02)
1 Values are adjusted geometric means (95% CIs) or ratios (95% CIs). Selenium and hemoglobin: HAART, n = 214; no HAART, n = 474;
LNS, n = 348; no LNS, n = 340. RBP: HAART, n = 214; no HAART, n = 473; LNS, n = 348; no LNS, n = 339. Ferritin: HAART, n = 215; no
HAART, n = 475; LNS, n = 349; no LNS, n = 341. Models controlled for season, baseline CD4 count, and baseline viral load. HAART 3 LNS
interactions were not significant (selenium: P = 0.45; RBP: P = 0.39; ferritin: P = 0.55; hemoglobin: P = 0.66). **Significant ratio, P , 0.01.
BAN, Breastfeeding, Antiretrovirals, and Nutrition; HAART, highly active antiretroviral therapy; LNS, lipid-based nutrient supplements; RBP,
retinol-binding protein.
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CD4 and prevalent vitamin A deficiency. Our results agree with
studies that showed that protease inhibitor–based HAART was
related to higher RBP or b-carotene compared with individuals
not receiving HAART (50, 51), whereas other studies found no
differences in vitamin A concentrations by HAART status or
type of HAART (12, 52). The variability in the literature points
to the need to examine how baseline vitamin A status, initial
CD4, and levels of inflammation influence changes in vitamin A
concentrations before and after HAART initiation.
LNS alone was not associated with ferritin, TfR, or hemo-
globin in this study. HAARTwas not associated with ferritin or
hemoglobin but was associated with higher TfR concentrations,
which indicates greater functional tissue iron deficiency in
women taking these drugs. TfR can be elevated when there is
iron-deficient erythropoiesis or tissue iron deficiency without
anemia (53), which may be more common in people with
chronic diseases and inflammation (54). The results on ferritin,
TfR, and hemoglobin reported here confirm our earlier findings
from a smaller, matched mother-infant subsample of BAN study
participants (55).
Women in the BAN study received standard iron-folic acid
tablets during pregnancy, as per Malawian guidelines, and their
hemoglobin concentrations were ;120 g/L on average both
after delivery and at 24 wk postpartum. This may explain the
lack of LNS effect on hemoglobin in our sample, whereas
increases in hemoglobin concentrations have been documented
in HIV-infected pregnant and lactating women with low initial
hemoglobin concentratons who were supplemented with mul-
tiple micronutrients (17). Our findings also differ from those of
several studies that showed increases in hemoglobin concentra-
tions in HIV patients after HAART initiation (8, 9, 56–58).
Some possible reasons for these differences include the short
duration of HAART therapy and inclusion of zidovudine in the
HAART regimen in our study. HAART has a more pronounced
effect on increasing hemoglobin in patients who have taken it for
>6 mo (56), whereas the use of zidovudine-containing HAART
causes lower hemoglobin concentrations in some individuals
(56, 58, 59).
This study had 3 main limitations. First, participants were
not randomly assigned to the different drugs. They took either
nelfinavir+Combivir or LPVr+Combivir on the basis of the
timing of their enrollment in the study. Although calendar time
could be related to our outcomes, we tried to limit possible
confounding by including season in the models. Second, this
analysis used a purposively selected subsample of mothers
enrolled in the BAN study. We initially planned to examine
effects in women with or without LNS. This resulted in a
subsample with relatively small numbers of participants in the
drug groups, which could limit our ability to detect differences.
Choosing a subsample can result in differences in characteristics
from the randomized cohort. Women in the micronutrient
subsample were slightly older and the proportion with low
CD4 counts or anemia was larger than in the rest of the BAN
participants. However, the actual differences between the
subsample and other study participants for these indicators
were so small as to be clinically insignificant. In addition, we
controlled for baseline CD4 count and viral load to address the
possibility of selection bias. Third, with the exception of
hemoglobin, we did not measure baseline micronutrient con-
centrations. We made this choice because micronutrient values
are typically lower in pregnancy, when screening occurred, and
would not allow us to look at changes related to the interven-
tions, which were implemented postpartum. Furthermore, we
would not expect to find differences in participants preinter-
vention micronutrient concentrations in a randomized trial. We
detected no differences between study arms in the proportion
who were anemic at baseline, mean baseline hemoglobin, or any
other baseline characteristic, suggesting that the groups were
well balanced before initiating the study interventions.
The HAART regimens provided in this study were first-line
treatment combinations at the time of study implementation and
are now used as second-line regimens in PMTCT programs. On
the basis of estimates of the proportion of patients who switch
regimens due to treatment failure, the results of this study are
applicable to ;100,000 women in sub-Saharan Africa who are
receiving second-line drugs in PMTCT programs (3, 60).
Anemia, iron deficiency, and inadequate folate status are
common in HIV-infected pregnant and lactating women in
Africa (61–63). If confirmed in larger studies, our findings on the
association of HAARTwith folate and TfR concentrations have
implications for the health of mothers and their infants and may
require supplementation or other types of interventions. Given
the recent rapid expansion of PMTCT programs, further
research is urgently needed to quantify the effects of second-
line HAART regimens and to study the association of first-line
regimens with micronutrient concentrations of women in
PMTCT.
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